Roche, Pfizer win FDA nods for targeted cancer drugs

Roche ($RHHBY) and Genentech won a landmark approval for the cancer drug vismodegib today. After gaining significant efficacy data from a Phase II study on basal cell carcinoma, the drug giant not only went straight to the regulators for a decision, but also won the approval well ahead of the agency's deadline. And top regulators signaled that they would look kindly on other developers who take the same approach to targeted therapeutics. The FDA nod comes on top of another targeted-drug approval Friday, for Pfizer's ($PFE) advanced kidney cancer drug axitinib, which will be marketed as Inlyta. Article | Report

Suggested Articles

An oncologist leader RBC Capital Markets interviewed expressed comfort that Trodelvy will succeed in earlier-line TNBC and in HR-positive disease.

Gilead Sciences is the latest drugmaker to settle Justice Department claims that its charity contributions were actually kickbacks.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.